Pa Shun International Holdings (HKSE:00574) ROE %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Pa Shun International Holdings ROE %?

Pa Shun International Holdings HKSE:00574 ROE % is 0.00% as of Dec. 2025. The stock has 9 warning signs investors should review. Among 623 Healthcare Providers & Services companies, Pa Shun International Holdings ranks worse than 160513.48% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Pa Shun International Holdings's annualized net income for the quarter that ended in Dec. 2025 was HK$-15.03 Mil. Pa Shun International Holdings's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was HK$-162.88 Mil. Therefore, Pa Shun International Holdings's annualized ROE % for the quarter that ended in Dec. 2025 was N/A%.

The historical rank and industry rank for Pa Shun International Holdings's ROE % or its related term are showing as below:

During the past 13 years, Pa Shun International Holdings's highest ROE % was 1.42%. The lowest was -313.74%. And the median was -15.81%.

HKSE:00574's ROE % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 6.25
* Ranked among companies with meaningful ROE % only.

Pa Shun International Holdings  (HKSE:00574) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2025 )
=Net Income/Total Stockholders Equity
=-15.026/-162.881
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-15.026 / 84.21)*(84.21 / 182.2555)*(182.2555 / -162.881)
=Net Margin %*Asset Turnover*Equity Multiplier
=-17.84 %*0.462*N/A
=ROA %*Equity Multiplier
=-8.24 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2025 )
=Net Income/Total Stockholders Equity
=-15.026/-162.881
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-15.026 / -14.616) * (-14.616 / 11.25) * (11.25 / 84.21) * (84.21 / 182.2555) * (182.2555 / -162.881)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0281 * -1.2992 * 13.36 % * 0.462 * N/A
=N/A %

Note: The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Pa Shun International Holdings ROE % Related Terms


Pa Shun International Holdings ROE % Historical Data

* Premium members only.

The historical data trend for Pa Shun International Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pa Shun International Holdings ROE % Chart

Pa Shun International Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -313.74 0.00 Negative Equity 0.00 0.00

Pa Shun International Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 Negative Equity 0.00 0.00 0.00

Pa Shun International Holdings ROE % Competitor Comparison

For the Pharmaceutical Retailers subindustry, Pa Shun International Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pa Shun International Holdings ROE % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Pa Shun International Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where Pa Shun International Holdings's ROE % falls into.



Pa Shun International Holdings ROE % Calculation

Pa Shun International Holdings's annualized ROE % for the fiscal year that ended in Dec. 2025 is calculated as

ROE %=Net Income (A: Dec. 2025 )/( (Total Stockholders Equity (A: Dec. 2024 )+Total Stockholders Equity (A: Dec. 2025 ))/ count )
=-17.517/( (-145.242+-163.478)/ 2 )
=-17.517/-154.36
=N/A %

Pa Shun International Holdings's annualized ROE % for the quarter that ended in Dec. 2025 is calculated as

ROE %=Net Income (Q: Dec. 2025 )/( (Total Stockholders Equity (Q: Jun. 2025 )+Total Stockholders Equity (Q: Dec. 2025 ))/ count )
=-15.026/( (-162.284+-163.478)/ 2 )
=-15.026/-162.881
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2025) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 0.00% mean?
Pa Shun International Holdings (HKSE:00574) has a ROE % of 0.00% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Pa Shun International Holdings and its competitors. According to the industry distribution chart, Pa Shun International Holdings ranks #999999 out of 623 companies in the Healthcare Providers & Services industry.
Is Pa Shun International Holdings' ROE % too high?
Pa Shun International Holdings' current ROE % is 0.00%. Based on the distribution chart, Pa Shun International Holdings ranks #999999 out of 623 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does Pa Shun International Holdings' ROE % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Pa Shun International Holdings ranks #999999 out of 623 companies for ROE %. This places Pa Shun International Holdings in the lower half of its industry. The industry median ROE % is 6.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 6.25, based on 623 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Pa Shun International Holdings and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 6.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pa Shun International Holdings's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pa Shun International Holdings stock overvalued right now?
Based on GuruFocus' analysis, Pa Shun International Holdings (HKSE:00574) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.03, compared to a current price of HK$0.02 — trading 40% below its estimated fair value. The current ROE % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Pa Shun International Holdings (HKSE:00574), the current ROE % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pa Shun International Holdings Business Description

Address 6- 8 Harbour Road, Suites 2601-2603, 26th Floor, Shui On Centre, Wanchai, Hong Kong, HKG
Pa Shun International Holdings Ltd is an investment holding company engaged in the manufacturing and distribution of pharmaceutical products. The business activity of the group is operated through Pharmaceutical distribution and Pharmaceutical manufacturing segment. Geographically all the activities are carried out in the PRC. The company derives the majority of revenue from the Pharmaceutical distribution segment which include sales of pharmaceutical products to wholesalers, franchise retail pharmacy chain stores and hospitals and other medical institutions in rural areas.